Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension

Drugs

Volumn 67, Issue 1, 2007, Pages 57-73

  Leibovitch, Leah ^a,b,c   Matok, Ilan ^a   Paret, Gideon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; DIGOXIN; DIPYRIDAMOLE; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; ILOPROST; ITRACONAZOLE; KETOCONAZOLE; MILRINONE; NITRIC OXIDE; NITROUS OXIDE; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; THEOPHYLLINE; UNIPROST; VASOCONSTRICTOR AGENT; ZAPRINAST;

ABDOMINAL DISCOMFORT; ANTICOAGULANT THERAPY; ARTIFICIAL VENTILATION; BACKACHE; BLURRED VISION; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONSTIPATION; DISEASE CLASSIFICATION; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DYSPEPSIA; ELECTROCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; EPISTAXIS; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART CATHETERIZATION; HEART FAILURE; HUMAN; HYPOTENSION; HYPOXEMIA; MENARCHE; NONHUMAN; OXYGEN THERAPY; OXYGENATION; PHYSICAL EXAMINATION; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHILD; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; VASODILATOR AGENTS;

ANIMALIA;

EID: 33846235179     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767010-00005     Document Type: Review

References (63)

1. Haworth SG. Primary pulmonary hypertension in childhood. Arch Dis Child 1998; 79: 452-5
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-9
3. Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr Pulmonol 2004; 38: 2-22
4. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5-12S
5. Rosenzweig EB, Barst RJ. Idiopathic pulmonary arterial hypertension in children. Curr Opin Pediatr 2005; 17: 372-80
6. Hoeper MM. Drug treatment of pulmonary arterial hypertension. Drugs 2005; 65: 1337-54
7. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 2003; 21: 155-76
8. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7
9. Ivy D. Diagnosis and treatment of severe pediatric pulmonary hypertension. Cardiol Rev 2001; 9: 227-37
10. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4
11. Loyd JE, Butler MG, Foroud TM, et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 152: 93-7
12. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000; 26: 81-4
13. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-44
14. Tulloh RM. Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev 2005; 6: 174-80
15. Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 2003; 36: 529-35
16. Greenough A, Khetriwal B. Pulmonary hypertension in the newborn. Paediatr Respir Rev 2005; 6: 111-6
17. Rich S, editor. Primary pulmonary hypertension: executive summary from the World Symposium-Primary Pulmonary Hypertension 1998. Geneva: World Health Organization, 1998
18. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005; 258: 199-215
19. Packer M, Medina N, Yushak M, et al. Detrimental effects of verapamil in patients with primary pulmonary hypertension. Br Heart J 1984; 52: 106-11
20. Frostell C, Fratacci MD, Wain JC, et al. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83: 2038-47
21. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336: 597-604
22. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000; 342: 469-74
23. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-82
24. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903
25. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697-706
26. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001; 108: 671-80
27. Rabe KF, Tenor H, Dent G, et al. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994; 266: 536-43
28. Carroll WD, Dhillon R. Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 2003; 88: 827-8
29. Galiè N, Ghofrani HA, Torbicki A, et al., for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-57
30. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52
31. Karatza AA, Bush A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100: 267-73
32. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002; 53 Suppl. 1: 5-12S
33. Zaiman A, Fijalkowska I, Hassoun PM, et al. One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol 2005; 33: 425-31
34. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-53
35. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 2002; 54: 404-9
36. Sastry BK, Narasimhan C, Reddy NK, et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 2002; 54: 410-4
37. Oliveira EC, Amaral CF. Sildenafil in the management of idiopathic pulmonary arterial hypertension in children and adolescents. J Pediatr (Rio J) 2005; 81: 390-4
38. Humpl T. Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274-80
39. Karatza AA, Narang I, Rosenthal M, et al. Treatment of primary pulmonary hypertension with oral sildenafil. Respiration 2004; 71: 192-4
40. Schulze-Neick I, Hartenstein P, Li J, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108 Suppl. 1: II167-73
41. Stocker C, Penny DJ, Brizard CP, et al. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 2003; 29: 1996-2003
42. Saygili A, Canter B, Iriz E, et al. Use of sildenafil with inhaled nitric oxide in the management of severe pulmonary hypertension. J Cardiothorac Vasc Anesth 2004; 18: 775-6
43. Kulkarni A, Singh TP, Sarnaik A, et al. Sildenafil for pulmonary hypertension after heart transplantation. J Heart Lung Transplant 2004; 23: 1441-4
44. Knoderer CA, Ebenroth ES, Brown JW. Chronic outpatient sildenafil therapy for pulmonary hypertension in a child after cardiac surgery. Pediatr Cardiol 2005; 26: 859-61
45. Raja SG, Nayak SH. Sildenafil: emerging cardiovascular indications. Ann Thorac Surg 2004; 78: 1496-506
46. McEniery JA, Delbridge RG, Reith DM. Infant pertussis deaths and the management of cardiovascular compromise. J Paediatr Child Health 2004; 40: 230-2
47. Hon KL, Cheung KL, Siu KL, et al. Oral sildenafil for treatment of severe pulmonary hypertension in an infant. Biol Neonate 2005; 88: 109-12
48. Chaudhari M, Vogel M, Wright C, et al. Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy. Arch Dis Child Fetal Neonatal Ed 2005; 90: 527-8
49. Ladha F, Bonnet S, Eaton F, et al. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 2005; 172: 750-6
50. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91: 307-10
51. Mychaskiw G, Sachdev V, Heath BJ. Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth 2001; 13: 218-20
52. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-403
53. Watanabe H, Ohashi K, Takeuchi K, et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002; 1: 398-402
54. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-22
55. Juliana AE, Abbad FC. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. Eur J Pediatr 2005; 164: 626-9
56. Baquero H, Soliz A. Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006; 117: 1077-83
57. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000; 92: 1702-12
58. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 1098-102
59. Ichinose F, Erana-Garcia J, Hromi J, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001; 29: 1000-5
60. Shekerdemian LS, Ravn HB, Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 2004; 55: 413-8
61. Symeonides S, Balk RA. Nitric oxide in the pathogenesis of sepsis. Infect Dis Clin North Am 1999; 13: 449-63
62. Marsh CS, Marden B, Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. Br J Ophthalmol 2004; 88: 306-7
63. Pierce CM, Petros AJ, Fielder AR. No evidence for severe retinopathy of prematurity following sildenafil. Br J Ophthalmol 2005; 89: 250